prognosis depends upon the histologic type of cancer (seminoma versus non-seminoma), stage, and other features such as tumor marker and type of metastatic disease. Cure rates for good-risk disease is nearly 90-95%.
Introduction
Primary testicular tumors are the most common solid malignant tumor in men between the ages of 20 and 35 years. For unknown reasons, the incidence of this cancer has increased during the last century 1 . Most testicular tumours are derived from the germ cells of the testis, although about 5% of testicular tumours are derived from other cells, including Leydig cells and lymphocytes (lymphoma) 2 .
The cause of testicular tumours is unknown, but several predisposing factors are recognized. Any solid, firm mass within the testis should be considered testicular cancer until proven otherwise. Prompt diagnosis and early treatment are required for cure. Testicular cancer may be painless, in which case they are sometimes ignored by the patient. In painful testicular swelling should be differentiated from epididymo-orchitis. The clinician should consider the full differential diagnosis of a testicular mass, which includes epididymo-orchitis, testicular torsion, hydrocele, hernia, hematoma, spermatocele, varicocele, and syphilitic gumma.
In the past, metastatic testicular cancer was usually fatal, but recent advances in treatment, including high-dose chemotherapy and stem cell rescue, have considerably improved the prognosis. Indeed, testicular cancer is a bright spot in the oncological landscape and are now considered to be the model for treatment of solid tumors3. Testicular cancers are highly curable, even in patients with metastatic disease at diagnosis. The
Discussion
Testicular cancer can occur at any age but is most common between the ages of 15 and 35 years. There is also secondary peak in incidence after age 60. Seminoma is rare in boys younger than 10 years of age but is the most common histologic type in men older than 60. Various risk factors have been associated with testicular tumors, but the specific etiology is not known. Cryptorchidism, genetic predisposition, family history and prior testicular cancers are important etiological factor.
Painless swelling or nodule of one testicle is the most common presenting symptom. On physical exam this mass/nodule can not be separated from the testis. Quick loss of testicular sensation could be presenting symptom also. Our patient presented with long 4 years history of slow growing painless swelling of the testis. Disseminated disease have symptom of lymphatic or hematogenous spread. Presenting symptoms could be neck mass in supraclavicular lymph node, anorexia, nausea and other gastrointestinal symptom. Bulky retroperitoneal disease could present as back pain. Cough, chest pain, hemoptysis and shortness of breath could be presenting symptom of mediastinal lymadenopathy or lung metastatic disease. Our patient did not have symptoms of chest symptom despite of pulmonary metastasis. 4 
Classification 4
Approximately 95% of testicular tumors are germ cell tumors. These are divided into two types: pure seminoma (no nonseminomatous element present) and nonseminomatous germ cell tumors (NSGCT)
A. Germ cell Tumour radical orchiectomy was done through inguinal approach. His abdominal lump and tenderness were reduced within a week of orchiectomy. Histology of the tumor showed combined variety of testicular carcinoma. On gross view the tumour had solid and cystic component. (Fig-A2 ) Microscopy revealed a combination of seminoma (Fig-A3 ) and embryonal carcinoma (Fig-A4 ) After healing of the wound patient was sent to oncologist in national Cancer Institute for further chemotherapy and radiotherapy. in 50-70% of NSGCT. It is not usually elevated in pure seminoma. Its half-life is about 5 days. β-human chorionic gonadotrophin (β-HCG) is produced by trophoblastic elements in the tumour. It is raised in 40 to 60% of NSGCTs and in up to 30% of pure seminomas. It has a half-life of 1 day. Lactate dehydrogenase (LDH) is less specific, but is more common in seminoma. Overall, 90% of NSGCTs elaborate at least one tumour marker, while markers are elevated in <40% of seminomas. Rise of α-fetoprotien in our patent was again due to presence of non-seminoma component. 
Poor-risk Seminoma

No Patients are Classified as Poor Prognosis
According to this risk classification our case falls under good risk non-seminomas. So final diagnosis becomes Stage IIIA mixed germ cell tumor and prognosis will be like good risk non seminomas. l Teratocarcinomas are part of the mixed germ cell tumor and are generally benign but have the potential for metastasis. They have elements from all three germ layers: ectoderm, endoderm, and mesoderm.
l Choriocarcinomas are the least common type of nonseminoma but are very aggressive. Widespread hematological metastasis can occur very early in the disease course; the retroperitoneum may be spared. Choriocarcinomas are associated with increased levels of β-hCG.
l Yolk cell tumors, also called endodermal sinus tumor, are the most common testicular tumor in infants and young children. In adults, pure yolk cell tumors are rare, but yolk cell elements are found in approximately 40% of mixed germ cell tumors. Yolk cell tumors are associated with elevated alpha fetoprotein levels but they do not produce β-hCG.
Mixed germ cell tumors have two or more germ cell types. These constitute approximately one third of testicular cancer. Mixed germ cell tumors behave like nonseminomas. The average age at diagnosis is older than 30 years. Our case falls in this category as it has two components seminoma and embryonal carcinoma.
Diagnostic Workup
Ultrasongram of the scrotum-USG has 100% accuracy for diagnosis of testicular malignancy. Seminoma appears as hypoechoic homogenous appearance. Nonseminoma appears as complex cystic and solid masses. Our patient showed typical combined solid and cystic component of mixed germ cell tumour. USG of the abdomen and Chest x-ray are minimum requirement for staging of the tumour. USG or CT Scan of the abdomen is necessary to see the enlargement of the para-aortic lymph nodes in the abdomen. This was very much positive in our case. Chest x-ray shows pulmonary metastasis in the form of multiple cannon ball especially in non-seminoma. This cannon ball in our case is due to the non-seminomatous component of the tumour.
Tumour Markers
Blood must be taken for marker evaluation before surgical removal of the testis. This is important for staging and also for postoperative follow up and to know the response of the treatment and surveillance. α-fetoprotein (AFP) is produced by the yolk sac elements and is elevated
Surgery for residual disease
Surgical resection is recommended for patients with residual disease after chemotherapy 10 . Laparoscopic LN dissection is recommended for stage I and II disease 11 . Retroperitoneal lymph node dissection (RPLND) should clear the region of residual disease. Open nerve-sparing RPLND is preferred over laparoscopic RPLND. Patients in whom RPLND reveals viable cancer, postchemotherapy residual masses are treated with subsequent chemotherapy 12 . We feel that our patient should receive chemotherapy as mentioned. He should be on active surveillance. Open RPLND may be needed if chemotherapy fails to control the residual disease in the abdomen. Pneumonectomy is also sometimes done for selected cases of pulmonary metastasis 13 .
Prognosis 14
Good-prognosis nonseminoma: 5 year survival is 90%.
Good-prognosis seminoma: 5-year survival is 85%
Intermediate-prognosis nonseminoma: 5-year survival is 80%
Intermediate-prognosis seminoma: 5-year survival is 70%
Poor-prognosis nonseminoma: 5-year survival is 70% Poor-prognosis s eminoma: No seminoma patients are classified as poor prognosis. 14 Our patient as good risk non seminoma has chance of survival of about 90% 5 year survival if he can receive all modalities of treatment discussed above.
Anatomical Diagnosis
Mixed germ cell tumour with combination of seminoma and embryonal carcinoma. Active surveillance-consists of a history and physical exam and measurement of AFP and hCG every 3 to 4 months for the first 3 years, every 6 months for years 4 to 7, then annually up to year 10. A CT scan of the abdomen and pelvis is recommended at each visit and a chest x-ray at alternate visits. It is essential that patients maintain strict adherence to the surveillance program for at least 10 years.
Adjuvant radiation therapy-consists of delivery of 20-30 Gy to the infradiaphragmatic area, including th paraaortic lymph nodes and in some cases the ipsilateral ileoinguinal nodes. According to surveillance data, the overall incidence of disease failure without radiation therapy is 15% to 25%. With radiation therapy, failure rates were 2% to 5%.
Adjuvant chemotherapy-with a single dose of carboplatin is currently recommended as an alternative to radiation therapy in stage I seminoma.
Nonseminoma stage IIIA good risk: Standard treatment is with three cycles of bleomycin, cisplatin and etoposide (BEP) given over 5 days at intervals of 22 days. The overall cure rate using this regimen is 90%. Bleomycine has pulmonary toxicity and side effects must be monitored closely.
